Ubs Group Ag Angion Biomedica Corp. Transaction History

Ubs Group Ag

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	BUY	$0.48 - $1.02 $2,195 - $4,664	4,573 Added 46.1%	14,492 $8,000
Q4 2022 Feb 08, 2023	BUY	$0.8 - $1.0 $2,143 - $2,679	2,679 Added 37.0%	9,919 $8,000
Q3 2022 Nov 10, 2022	SELL	$0.94 - $1.23 $3,505 - $4,586	-3,729 Reduced 34.0%	7,240 $7,000
Q2 2022 Aug 10, 2022	BUY	$1.1 - $2.23 $11,553 - $23,421	10,503 Added 2253.86%	10,969 $12,000
Q1 2022 May 16, 2022	SELL	$1.72 - $2.96 $13,882 - $23,890	-8,071 Reduced 94.54%	466 $1,000
Q4 2021 Feb 14, 2022	BUY	$2.35 - $9.95 $20,061 - $84,943	8,537 New	8,537 $25,000
Q3 2021 Nov 15, 2021	SELL	$9.31 - $13.25 $2,020 - $2,875	-217 Closed	0 $0
Q2 2021 Aug 13, 2021	SELL	$13.02 - $17.83 $18,397 - $25,193	-1,413 Reduced 86.69%	217 $3,000
Q1 2021 May 12, 2021	BUY	$15.01 - $25.74 $24,466 - $41,956	1,630 New	1,630 $29,000

Ticker ANGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 30,113,300
Description
Angion Biomedica Corp., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapeutics for acute organ injuries and fibrotic diseases. The company's lead product candidate is ANG-3070, an oral tyrosine kinase receptor inhibitor in development as a treatment for fibrotic diseases, primaril...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.